The role of beta amyloid in Alzheimer's disease: Still a cause of everything or the only one who got caught?

Pharmacological Research

Volumn 50, Issue 4, 2004, Pages 397-409

  Verdile, Giuseppe ^a,d   Fuller, Stephanie ^b   Atwood, Craig S ^c,d   Laws, Simon M ^a,d   Gandy, Samuel E ^d,e   Martins, Ralph N ^a,d  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d EDITH COWAN UNIVERSITY   (Australia)

^e Farber Inst Neurosci Thomas J   (United States)

Author keywords

Alzheimer's disease; Amyloid beta protein; Amyloid precursor protein; Presenilin; Tau

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID PRECURSOR PROTEIN; ANTIBODY; CLIOQUINOL; CURCUMIN; ESTRADIOL; ESTROGEN; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; HOMOTAURINE; IBUPROFEN; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; SULINDAC; TESTOSTERONE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; DISEASE ASSOCIATION; GENE MUTATION; GENETIC LINKAGE; HUMAN; MEDICAL RESEARCH; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN STRUCTURE; THEORETICAL STUDY;

ALZHEIMER DISEASE; ALZHEIMER VACCINES; AMYLOID BETA-PROTEIN; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPARTIC ENDOPEPTIDASES; CHELATION THERAPY; ENDOPEPTIDASES; ENZYME INHIBITORS; HORMONES; HUMANS; MUTATION;

EID: 4043088415     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phrs.2003.12.028     Document Type: Article

References (127)

1. Glenner G.G., Wong C.W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120:1984;885-890
2. Masters C.L., Simms G., Weinman N.A., Multhaup G., McDonald B.L., Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. U.S.A. 82:1985;4245-4249
3. Martins R.N., Robinson P.J., Chleboun J.O., Beyreuther K., Masters C.L. The molecular pathology of amyloid deposition in Alzheimer's disease. Mol. Neurobiol. 5:1991;389-398
4. Klafki H.W., Wiltfang J., Staufenbiel M. Electrophoretic separation of betaA4 peptides (1-40) and (1-42). Anal. Biochem. 237:1996;24-29
5. Asami-Odaka A., Ishibashi Y., Kikuchi T., Kitada C., Suzuki N. Long amyloid beta-protein secreted from wild-type human neuroblastoma IMR-32 cells. Biochemistry. 34:1995;10272-10278
6. Lippa C.F., Nee L.E., Mori H., St. George-Hyslop P. Abeta-42 deposition precedes other changes in PS-1 Alzheimer's disease. Lancet. 352:1998;1117-1118. [letter]
7. Hensley K., Carney J.M., Mattson M.P., Aksenova M., Harris M., Wu J.F., et al. A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 91:1994;3270-3274
8. Nunan J., Small D.H. Regulation of APP cleavage by alpha-, beta- and gamma-secretases. FEBS Lett. 483:2000;6-10. [review]
9. Gandy S., Petanceska S. Regulation of alzheimer beta-amyloid precursor trafficking and metabolism. Adv. Exp. Med. Biol. 487:2001;85-100
10. Pinnix I., Musunuru U., Tun H., Sridharan A., Golde T., Eckman C., et al. A novel gamma-secretase assay based on detection of the putative C-terminal fragment-gamma of amyloid beta protein precursor. J. Biol. Chem. 276:2001;481-487
11. Urban S., Freeman M. Intramembrane proteolysis controls diverse signalling pathways throughout evolution. Curr. Opin. Genet. Dev. 12:2002;512-518
12. Paetzel M., Dalbey R.E., Strynadka N.C. Crystal structure of a bacterial signal peptidase in complex with a beta-lactam inhibitor. Nature. 396:1998;186-190
13. Iwata S., Lee J.W., Okada K., Lee J.K., Iwata M., Rasmussen B., et al. Complete structure of the 11-subunit bovine mitochondrial cytochrome bc1 complex. Science. 281:1998;64-71
14. Tandon A, Fraser P. The presenilins. Genome Biol 2002;3:3014.
15. Destrooper B., Saftig P., Craessaerts K., Vanderstichele H., Guhde G., Annaert W., et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature. 391:1998;387-390
16. Wolfe M.S. Gamma-secretase inhibitors as molecular probes of presenilin function. J. Mol. Neurosci. 17:2001;199-204
17. Verdile G., Martins R.N., Duthie M., Holmes E., St. George-Hyslop P.H., Fraser P.E. Inhibiting amyloid precursor protein C-terminal cleavage promotes an interaction with presenilin 1. J. Biol. Chem. 275:2000;20794-20798
18. Li Y.M., Lai M.T., Xu M., Huang Q., DiMuzio-Mower J., Sardana M.K., et al. Presenilin 1 is linked with gamma-secretase activity in the detergent solubilized state. Proc. Nat. Acad. Sci. U.S.A. 97:2000;6138-6143
19. Haass C., Steiner H. Alzheimer disease gamma-secretase: a complex story of GxGD-type presenilin proteases. Trends Cell Biol. 12:2002;556-562
20. Francis R., McGrath G., Zhang J., Ruddy D.A., Sym M., Apfeld J., et al. aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation. Dev. Cell. 3:2002;85-97
21. Edbauer D., Winkler E., Regula J.T., Pesold B., Steiner H., Haass C. Reconstitution of gamma-secretase activity. Nat. Cell Biol. 5:2003;486-488
22. Cummings B.J., Pike C.J., Shankle R., Cotman C.W. Beta-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease. Neurobiol. Aging. 17:1996;921-933
23. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., et al. Diffusible, nonfibrillar ligands derived from Abeta1 to 42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U.S.A. 95:1998;6448-6453
24. Walsh D.M., Hartley D.M., Kusumoto Y., Fezoui Y., Condron M.M., Lomakin A., et al. Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J. Biol. Chem. 274:1999;25945-25952
25. Holcomb L., Gordon M.N., McGowan E., Yu X., Benkovic S., Jantzen P., et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 4:1998;97-100
26. Lue L.F., Kuo Y.M., Roher A.E., Brachova L., Shen Y., Sue L., et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 155:1999;853-862
27. Westerman M.A., Cooper-Blacketer D., Mariash A., Kotilinek L., Kawarabayashi T., Younkin L.H., et al. The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci. 22:2002;1858-1867
28. Lewis J., Dickson D.W., Lin W.L., Chisholm L., Corral A., Jones G., et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 293:2001;1487-1491
29. Gotz J., Chen F., van Dorpe J., Nitsch R.M. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science. 293:2001;1491-1495
30. Noble W., Olm V., Takata K., Casey E., Mary O., Meyerson J., et al. Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron. 38:2003;555-565
31. Pike C.J., Burdick D., Walencewicz A.J., Glabe C.G., Cotman C.W. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci. 13:1993;1676-1687
32. Hartley D.M., Walsh D.M., Ye C.P., Diehl T., Vasquez S., Vassilev P.M., et al. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J. Neurosci. 19:1999;8876-8884
33. Xia W., Zhang J., Kholodenko D., Citron M., Podlisny M.B., Teplow D.B., et al. Enhanced production and oligomerization of the 42-residue amyloid beta-protein by Chinese hamster ovary cells stably expressing mutant presenilins. J. Biol. Chem. 272:1997;7977-7982
34. Hsia A.Y., Masliah E., McConlogue L., Yu G.Q., Tatsuno G., Hu K., et al. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc. Natl. Acad. Sci. U.S.A. 96:1999;3228-3233
35. Tanzi R.E., George-Hyslop P.S., Gusella J.F. Molecular genetics of Alzheimer disease amyloid. J. Biol. Chem. 266:1991;20579-20582
36. St. George-Hyslop P.H., Tanzi R.E., Polinsky R.J., Neve R.L., Pollen D., Drachman D., et al. Absence of duplication of chromosome 21 genes in familial and sporadic Alzheimer's disease. Science. 238:1987;664-666
37. Tanzi R.E., Gusella J.F., Watkins P.C., Bruns G.A., St George-Hyslop P., Van Keuren M.L., et al. Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science. 235:1987;880-884
38. Van Broeckhoven C., Genthe A.M., Vandenberghe A., Horsthemke B., Backhovens H., Raeymaekers P., et al. Failure of familial Alzheimer's disease to segregate with the A4-amyloid gene in several European families. Nature. 329:1987;153-155
39. Murrell J., Farlow M., Ghetti B., Benson M.D. A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science. 254:1991;97-99
40. Goate A., Chartier-Harlin M.C., Mullan M., Brown J., Crawford F., Fidani L., et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 349:1991;704-706. [see comments]
41. Checler F. Processing of the beta-amyloid precursor protein and its regulation in Alzheimer's disease. J. Neurochem. 65:1995;1431-1444
42. Suzuki N., Cheung T.T., Cai X.D., Odaka A., Otvos L. Jr., Eckman C., et al. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science. 264:1994;1336-1340
43. Iwatsubo T., Odaka A., Suzuki N., Mizusawa H., Nukina N., Ihara Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron. 13:1994;45-53
44. Nilsberth C., Westlind-Danielsson A., Eckman C.B., Condron M.M., Axelman K., Forsell C., et al. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced abeta protofibril formation. Nat. Neurosci. 4:2001;887-893
45. Levy E., Carman M.D., Fernandez-Madrid I.J., Power M.D., Lieberburg I., van Duinen S.G., et al. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science. 248:1990;1124-1126
46. Rossor M.N., Fox N.C., Beck J., Campbell T.C., Collinge J. Incomplete penetrance of familial Alzheimer's disease in a pedigree with a novel presenilin-1 gene mutation. Lancet. 347:1996;1560. [letter]
47. Helisalmi S., Hiltunen M., Mannermaa A., Koivisto A.M., Lehtovirta M., Alafuzoff I., et al. Is the presenilin-1 E318G missense mutation a risk factor for Alzheimer's disease? Neurosci. Lett. 278:2000;65-68
48. Taddei K., Fisher C., Laws S.M., Martins G., Paton A., Clarnette R.M., et al. Association between presenilin-1 Glu318Gly mutation and familial Alzheimer's disease in the Australian population. Mol. Psychiatry. 7:2002;776-781
49. Scheuner D., Eckman C., Jensen M., Song X., Citron M., Suzuki N., et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 2:1996;864-870. [see comments]
50. Borchelt D.R., Thinakaran G., Eckman C.B., Lee M.K., Davenport F., Ratovitsky T., et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron. 17:1996;1005-1013
51. Citron M., Westaway D., Xia W., Carlson G., Diehl T., Levesque G., et al. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat. Med. 3:1997;67-72. [see comments]
52. Lemere C.A., Lopera F., Kosik K.S., Lendon C.L., Ossa J., Saido T.C., et al. The E280a presenilin 1 Alzheimer mutation produces increased a-beta-42 deposition and severe cerebellar pathology. Nat. Med. 2:1996;1146-1150
53. Ishii K., Ii K., Hasegawa T., Shoji S., Doi A., Mori H. Increased a-beta 42(43)-plaque deposition in early-onset familial Alzheimers-disease brains with the deletion of exon 9 and the missense point mutation (H163r) in the ps-1 gene. Neuro. Lett. 228:1997;17-20
54. Duff K., Eckman C., Zehr C., Yu X., Prada C.M., Pereztur J. Increased amyloid-beta-42(43) in brains of mice expressing mutant presenilin 1. Nature. 383:1996;710-713
55. Citron M., Diehl T.S., Gordon G., Biere A.L., Seubert P., Selkoe D.J. Evidence that the 42- and 40-amino acid forms of amyloid beta protein are generated from the beta-amyloid precursor protein by different protease activities. Proc. Natl. Acad. Sci. U.S.A. 93:1996;13170-13175
56. Murphy M.P., Hickman L.J., Eckman C.B., Uljon S.N., Wang R., Golde T.E. Gamma-secretase, evidence for multiple proteolytic activities and influence of membrane positioning of substrate on generation of amyloid beta peptides of varying length. J. Biol. Chem. 274:1999;11914-11923
57. Hartmann T., Bieger S.C., Bruhl B., Tienari P.J., Ida N., Allsop D., et al. Distinct sites of intracellular production for Alzheimer's disease a-beta40/42 amyloid peptides. Nat. Med. 3:1997;1016-1020
58. Lichtenthaler S.F., Wang R., Grimm H., Uljon S.N., Masters C.L., Beyreuther K., et al. Mechanism of the cleavage specificity of Alzheimer's disease gamma-secretase identified by phenylalanine-scanning mutagenesis of the transmembrane domain of the amyloid precursor protein. Proc. Nat. Acad. Sci. U.S.A. 96:1999;3053-3058
59. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81:2001;741-766
60. Mudher A., Lovestone S. Alzheimer's disease-do tauists and baptists finally shake hands? Trends Neurosci. 25:2002;22-26
61. Mena R., Edwards P.C., Harrington C.R., Mukaetova-Ladinska E.B., Wischik C.M. Staging the pathological assembly of truncated tau protein into paired helical filaments in Alzheimer's disease. Acta Neuropathol. 91:1996;633-641
62. Nagy Z., Esiri M.M., Jobst K.A., Morris J.H., King E.M., et al. Relative roles of plaques and tangles in the dementia of Alzheimer's disease: correlations using three sets of neuropathological criteria. Dementia. 6:1995;21-31
63. Braak H., Braak E. Morphological criteria for the recognition of Alzheimer's disease and the distribution pattern of cortical changes related to this disorder. Neurobiol. Aging. 15:1994;355-356. discussion 379-380
64. Naslund J., Haroutunian V., Mohs R., Davis K.L., Davies P., Greengard P., et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA. 283:2000;1571-1577
65. Godemann R., Biernat J., Mandelkow E., Mandelkow E.M. Phosphorylation of tau protein by recombinant GSK-3beta: pronounced phosphorylation at select Ser/Thr-Pro motifs but no phosphorylation at Ser262 in the repeat domain. FEBS Lett. 454:1999;157-164
66. Ko L.W., DeTure M., Sahara N., Chihab R., Yen S.H. Cellular models for tau filament assembly. J. Mol. Neurosci. 19:2002;311-316
67. Rank K.B., Pauley A.M., Bhattacharya K., Wang Z., Evans D.B., Fleck T.J., et al. Direct interaction of soluble human recombinant tau protein with Abeta 1-42 results in tau aggregation and hyperphosphorylation by tau protein kinase II. FEBS Lett. 514:2002;263-268
68. Tomidokoro Y., Ishiguro K., Harigaya Y., Matsubara E., Ikeda M., Park J.M., et al. Abeta amyloidosis induces the initial stage of tau accumulation in APP(Sw) mice. Neurosci. Lett. 299:2001;169-172
69. Ferreira A., Lu Q., Orecchio L., Kosik K.S. Selective phosphorylation of adult tau isoforms in mature hippocampal neurons exposed to fibrillar A beta. Mol. Cell Neurosci. 9:1997;220-234
70. Hoshi M., Sato M., Matsumoto S., Noguchi A., Yasutake K., Yoshida N., et al. Spherical aggregates of {beta}-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3{beta}. Proc. Natl. Acad. Sci. U.S.A. 100:2003;6370-6375
71. Town T., Zolton J., Shaffner R., Schnell B., Crescentini R., Wu Y., et al. p35/Cdk5 pathway mediates soluble amyloid-beta peptide-induced tau phosphorylation in vitro. J. Neurosci. Res. 69:2002;362-372
72. Small D.H., Mok S.S., Bornstein J.C. Alzheimer's disease and Abeta toxicity: from top to bottom. Nat. Rev. Neurosci. 2:2001;595-598
73. Cuajungco M.P., Goldstein L.E., Nunomura A., Smith M.A., Lim J.T., Atwood C.S., et al. Evidence that the beta-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of Abeta by zinc. J. Biol. Chem. 275:2000;19439-19442
74. Rottkamp C.A., Raina A.K., Zhu X.W., Gaier E., Bush A.I., Atwood C.S. Redox-active iron mediates amyloid-beta toxicity. Free Rad. Biol. Med. 30:2001;447-450
75. Huang X., Atwood C.S., Hartshorn M.A., Multhaup G., Goldstein L.E., Scarpa R.C., et al. The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry. 38:1999;7609-7616
76. Butterfield D.A., Lauderback C.M. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Rad. Biol. Med. 32:2002;1050-1060
77. Bondy S.C., Guo-Ross S.X., Truong A.T. Promotion of transition metal-induced reactive oxygen species formation by beta-amyloid. Brain Res. 799:1998;91-96
78. Varadarajan S., Yatin S., Kanski J., Jahanshahi F., Butterfield D.A. Methionine residue 35 is important in amyloid beta-peptide-associated free radical oxidative stress. Brain Res. Bull. 50:1999;133-141
79. Chan C., Dharmarajan A., Atwood C.S., Huang X., Tanzi R.E., Bush A.I., et al. Anti-apoptotic action of Alzheimer Ab. Alzheimer. Rep. 2:1999;113-119
80. Liu S.T., Howlett G., Barrow C.J. Histidine-13 is a crucial residue in the zinc ion-induced aggregation of the A beta peptide of Alzheimer's disease. Biochemistry. 38:1999;9373-9378
81. Atwood C.S., Scarpa R.C., Huang X., Moir R.D., Jones W.D., Fairlie D.P., et al. Characterization of copper interactions with alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta1-42. J. Neurochem. 75:2000;1219-1233
82. Curtain C.C., Ali F.E., Smith D.G., Bush A.I., Masters C.L., Barnham K.J. Metal ions, pH, and cholesterol regulate the interactions of Alzheimer's disease amyloid-beta peptide with membrane lipid. J. Biol. Chem. 278:2003;2977-2982
83. Weiner H.L., Selkoe D.J. Inflammation and therapeutic vaccination in CNS diseases. Nature. 420:2002;879-884
84. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., et al. Inflammation and Alzheimer's disease. Neurobiol. Aging. 21:2000;383-421
85. Wyss-Coray T., Masliah E., Mallory M., McConlogue L., Johnson-Wood K., Lin C., et al. Amyloidogenic role of cytokine TGF-beta1 in transgenic mice and in Alzheimer's disease. Nature. 389:1997;603-606
86. Webster S., Bonnell B., Rogers J. Charge-based binding of complement component C1q to the Alzheimer amyloid beta-peptide. Am. J. Pathol. 150:1997;1531-1536
87. Dovey H.F., John V., Anderson J.P., Chen L.Z., de Saint Andrieu P., Fang L.Y., et al. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J. Neurochem. 76:2001;173-181
88. Gandy S. Molecular basis for anti-amyloid therapy in the prevention and treatment of Alzheimer's disease. Neurobiol. Aging. 23:2002;1009-1016
89. Hadland B.K., Manley N.R., Su D., Longmore G.D., Moore C.L., Wolfe M.S., et al. Gamma-secretase inhibitors repress thymocyte development. Proc. Natl. Acad. Sci. U.S.A. 98:2001;7487-7491
90. Luo Y., Bolon B., Kahn S., Bennett B.D., Babu-Khan S., Denis P., et al. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat. Neurosci. 4:2001;231-232
91. Golde T.E. Alzheimer disease therapy: can the amyloid cascade be halted? J. Clin. Invest. 111:2003;11-18
92. Chang D., Kwan J., Timiras P.S. Estrogens influence growth, maturation, and amyloid beta-peptide production in neuroblastoma cells and in a beta-APP transfected kidney 293 cell line. Adv. Exp. Med. Biol. 429:1997;261-271
93. Xu H., Gouras G.K., Greenfield J.P., Vincent B., Naslund J., Mazzarelli L., et al. Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides. Nat. Med. 4:1998;447-451
94. Petanceska S.S., Nagy V., Frail D., Gandy S. Ovariectomy and 17beta-estradiol modulate the levels of Alzheimer's amyloid beta peptides in brain. Exp. Gerontol. 35:2000;1317-1325
95. Zheng H., Xu H., Uljon S.N., Gross R., Hardy K., Gaynor J., et al. Modulation of A(beta) peptides by estrogen in mouse models. J. Neurochem. 80:2002;191-196
96. Goodman Y., Bruce A.J., Cheng B., Mattson M.P. Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid beta-peptide toxicity in hippocampal neurons. J. Neurochem. 66:1996;1836-1844
97. Green P.S., Gridley K.E., Simpkins J.W. Estradiol protects against beta-amyloid (25-35)-induced toxicity in SK-N-SH human neuroblastoma cells. Neurosci. Lett. 218:1996;165-168
98. Gollapudi L., Oblinger M.M. Stable transfection of PC12 cells with estrogen receptor (ERalpha): protective effects of estrogen on cell survival after serum deprivation. J. Neurosci. Res. 56:1999;99-108
99. Kim H., Bang O.Y., Jung M.W., Ha S.D., Hong H.S., Huh K., et al. Neuroprotective effects of estrogen against beta-amyloid toxicity are mediated by estrogen receptors in cultured neuronal cells. Neurosci. Lett. 302:2001;58-62
100. Marin R., Guerra B., Morales A., Diaz M., Alonso R. An oestrogen membrane receptor participates in estradiol actions for the prevention of amyloid-beta peptide1-40-induced toxicity in septal-derived cholinergic SN56 cells. J. Neurochem. 85:2003;1180-1189
101. Pike C.J. Testosterone attenuates beta-amyloid toxicity in cultured hippocampal neurons. Brain Res. 919:2001;160-165
102. Mattson M.P., Cheng B., Culwell A.R., Esch F.S., Lieberburg I., Rydel R.E. Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein. Neuron. 10:1993;243-254
103. Goodman Y., Mattson M.P. Secreted forms of beta-amyloid precursor protein protect hippocampal neurons against amyloid beta-peptide-induced oxidative injury. Exp. Neurol. 128:1994;1-12
104. Goodenough S., Engert S., Behl C. Testosterone stimulates rapid secretory amyloid precursor protein release from rat hypothalamic cells via the activation of the mitogen-activated protein kinase pathway. Neurosci. Lett. 296:2000;49-52
105. Smith-Swintosky V.L., Mattson M.P. Glutamate, beta-amyloid precursor proteins, and calcium mediated neurofibrillary degeneration. J. Neural. Transm. Suppl. 44:1994;29-45
106. Gandy S., Almeida O.P., Fonte J., Lim D., Waterrus A., Spry N., et al. Chemical andropause and amyloid-beta peptide. JAMA. 285:2001;2195-2196
107. Humphries K.H., Gill S. Risks and benefits of hormone replacement therapy: the evidence speaks. CMAJ. 168:2003;1001-1010
108. Rapp S.R., Espeland M.A., Shumaker S.A., Henderson V.W., Brunner R.L., Manson J.E., et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: The Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 289:2003;2663-2672
109. Shumaker S.A., Legault C., Thal L., Wallace R.B., Ockene J.K., Hendrix S.L., et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 289:2003;2651-2662
110. Weggen S., Eriksen J.L., Das P., Sagi S.A., Wang R., Pietrzik C.U., et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature. 414:2001;212-216
111. Lim G.P., Chu T., Yang F., Beech W., Frautschy S.A., Cole G.M., et al. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci. 21:2001;8370-8377
112. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 400:1999;173-177
113. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6:2000;916-919
114. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., et al. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 98:2001;8850-8855
115. Das P., Murphy M.P., Younkin L.H., Younkin S.G., Golde T.E. Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol. Aging. 22:2001;721-727
116. Dodart J.C., Bales K.R., Gannon K.S., Greene S.J., DeMattos R.B., Mathis C., et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci. 5:2002;452-457
117. Orgogozo J.M., Gilman S., Dartigues J.F., Laurent B., Puel M., Kirby L.C., et al. Subacute meningoencephalitis in a subset of patients with AD after Ab42 immunisation. Neurology. 61:2003;46-54
118. Furlan R., Brambilla E., Sanvito F., Roccatagliata L., Olivieri S., Bergami A., et al. Vaccination with amyloid-beta peptide induces autoimmune encephalomyelitis in C57/BL6 mice. Brain. 126:2003;285-291
119. Hock C., Konietzko U., Streffer J.R., Tracy J., Signorell A., Muller-Tillmanns B., et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron. 38:2003;547-554
120. McLaurin J., Cecal R., Kierstead M.E., Tian X., Phinney A.L., Manea M., et al. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat. Med. 8:2002;1263-1269
121. Bush A.I. Metal complexing agents as therapies for Alzheimer's disease. Neurobiol. Aging. 23:2002;1031-1038
122. Cherny R.A., Atwood C.S., Xilinas M.E., Gray D.N., Jones W.D., McLean C.A., et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron. 30:2001;665-676
123. Tateishi J. Subacute myelo-optico-neuropathy: clioquinol intoxication in humans and animals. Neuropathology. 20:2000;S20-S24
124. Kisilevsky R. Review: amyloidogenesis-unquestioned answers and unanswered questions. J. Struct. Biol. 130:2000;99-108
125. McLaurin J., Franklin T., Kuhns W.J., Fraser P.E. A sulfated proteoglycan aggregation factor mediates amyloid-beta peptide fibril formation and neurotoxicity. Amyloid. 6:1999;233-243
126. Yang D.S., Yip C.M., Huang T.H., Chakrabartty A., Fraser P.E. Manipulating the amyloid-beta aggregation pathway with chemical chaperones. J. Biol. Chem. 274:1999;32970-32974
127. Robinson S.R., Bishop G.M. Abeta as a bioflocculant: implications for the amyloid hypothesis of Alzheimer's disease. Neurobiol. Aging. 23:2002;1051-1072